India’s Ophthalmic Market Expected to Total $US1.9 Billion by 2021

June 17, 2016: By Market Scope

Market Scope forecasts that India’s US$1.4 billion ophthalmic market is expected to grow at a compound annual rate (CAGR) of 6.5 percent a year to $US1.9 billion by 2021.

India is the second most populous country in the world and has tremendous unmet need for ophthalmic care. The country is home to 18 percent of the world’s population and approximately 30 percent of the world’s blind people. Over the past 70 years, India’s life expectancy rate has seen exceptional growth from a life expectancy of age 27 in 1947 to age 70 in 2016. By 2021, more than 10 percent of the population—over 140 million people—will be age 60 or over. Additional factors expected to fuel India’s ophthalmic market growth include an upsurge in dietary change-related eye diseases, growing incidence of myopia, a growing middle class, and improved access to care. In terms of treatments for diseases or disorders, the largest markets are for cataract surgery, retinal drugs, and glaucoma medications.

Cataract products are the largest ophthalmic surgical submarket in India. Revenues from cataract surgery in India are expected to generate nearly one-fourth of the total ophthalmic market revenues in the country. Market Scope estimates that India’s cataract market will total US$533.7 million by 2021, growing at a CAGR of 9.3 percent. Small-incision cataract surgery (SICS) is the dominant surgical procedure used to remove cataracts, accounting for over half of all cataract surgeries, but ultrasonic phacoemulsification is gaining ground. Femtosecond laser-assisted cataract surgery is just beginning to have a presence in the market. Surgeons typically use foldable IOLs and ophthalmic viscoelastic devices with either SICS or phacoemulsification.

Retinal disease is the second-leading cause of blindness in India, fueled in part by a high incidence of myopia. Retinal products are the second-largest ophthalmic revenue market in India due to the importance of anti-VEGFs in treatment. Market Scope expects India’s retinal disease market to fluctuate over the next five years as new biosimilar anti-VEGFs enter the market, but we look for revenues to remain relatively flat, totaling US$232 million in 2021.

Glaucoma, the third-largest ophthalmic submarket in India, is mainly a pharmaceutical market, and the main driver of revenue growth will be better access to glaucoma medicines. Market Scope forecasts that India’s glaucoma market will increase to US$296.5 million by 2021 at a CAGR of 10.8 percent.

Market Scope estimates that there are more than 180 companies competing in India’s ophthalmic market. Twelve companies (Alcon, Carl Zeiss Meditec, Bausch + Lomb, Genentech/Roche, Allergan, Abbott Medical Optics, Bayer Healthcare AG, Santen, Topcon, Nidek, Cipla Limited, and Sun Pharmaceutical Industries Ltd.) make up more than two-thirds of manufacturer revenues, leaving the smaller market players competing for the remaining 30 percent of the ophthalmic market opportunity in India.

Market Scope published its 2016 India Ophthalmic Market Report: An Analysis for 2015 to 2021 in June 2016. Our report includes a comprehensive overview of the population and economic conditions in India. We cover prevalence and forecasts for eye diseases and conditions. We discuss therapeutic approaches (including those unique to India) and describe both commercialized products and products in the pipeline. Our report also examines the outlook for dry eye treatments, diagnostic equipment, surgical instruments, and single-use surgical devices. We analyze unit demand and revenues and forecast future performance over the next five years. We also include market share data and discuss key strategic issues.

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT